MRCPCH

Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Real-World, Evidence-Based Approaches for Individualized Treatment in Adults w

Retrieved on: 
Monday, October 23, 2023
MB, Jazz Pharmaceuticals, Sodium, Mercury (element), Literature, Blood pressure, Congress, Narcolepsy, MD, Observational study, American Heart Association, Cataplexy, Disease, Idiopathic hypersomnia, Systematic review, Gamma-Hydroxybutyric acid, Sleep, Magnesium, American Heart, Risk, Somnolence, Colorado Ultraviolet Transit Experiment, Patient, Calcium, MRCPCH, Potassium, Medicine, Diagnosis, Cardiovascular disease, Mercury, Salt, Pharmaceutical industry, Person, Sodium oxybate, Xywav

DUBLIN, Oct. 23, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new data that examine the comorbid risk of cardiovascular disease in patients with narcolepsy and idiopathic hypersomnia as well as the effect of sodium intake on cardiovascular health. The Company will also present results from the real-world TENOR study on individualized dosing regimens for adults with type 1 or type 2 narcolepsy transitioning to low-sodium Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution from high-sodium Xyrem® (sodium oxybate) oral solution. The study will be presented today at the World Sleep 2023 Congress in an oral session on evidence-based approaches for optimizing pharmacologic treatment for narcolepsy.

Key Points: 
  • The Company will also present results from the real-world TENOR study on individualized dosing regimens for adults with type 1 or type 2 narcolepsy transitioning to low-sodium Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution from high-sodium Xyrem® (sodium oxybate) oral solution.
  • The study will be presented today at the World Sleep 2023 Congress in an oral session on evidence-based approaches for optimizing pharmacologic treatment for narcolepsy.
  • "Real-world data regarding individualized dosing regimens for the treatment of narcolepsy are limited.
  • The TENOR study was a patient-centric, prospective, observational study of U.S. adults with type 1 or type 2 narcolepsy.

Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023

Retrieved on: 
Monday, September 11, 2023
Psych, Abstract, Abstract (summary), Bachelor of Medicine, Bachelor of Surgery, Narcolepsy, Depression, University, Idiopathic hypersomnia, Magnesium, Anxiety, Safety, Efficacy, Quality of life, Medical school, Research, Mental health, Disruption, Calcium, DSM-IV codes, Literature, Patient, Sleep disorder, Physician, Psychiatry, FCCP, MRCPCH, Jazz Pharmaceuticals, Potassium, Pharmaceutical industry, Sleep, Gamma-Hydroxybutyric acid, MD, Medicine

DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023. One of the accepted abstracts provided a comprehensive review of clinical data that assessed the impact of oxybate on sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy. Oxybate is the active ingredient in Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution.

Key Points: 
  • Review of multiple clinical trials provided a comprehensive analysis showing that oxybate improves sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy, independent of once- or twice-nightly dosing
    DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023.
  • One of the accepted abstracts provided a comprehensive review of clinical data that assessed the impact of oxybate on sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy.
  • The review found that oxybate improved measures of sleep architecture and disrupted nighttime sleep in narcolepsy patients, independent of dosing regimen or prior oxybate experience.
  • "Idiopathic hypersomnia has a profound impact on those who live with this debilitating sleep disorder," said Kelvin Tan, MBBCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals.

Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023

Retrieved on: 
Monday, September 11, 2023
Psych, Abstract, Abstract (summary), Bachelor of Medicine, Bachelor of Surgery, Narcolepsy, Depression, University, Idiopathic hypersomnia, Magnesium, Anxiety, Safety, Efficacy, Quality of life, Medical school, Research, Mental health, Disruption, Calcium, DSM-IV codes, Literature, Patient, Sleep disorder, Physician, Psychiatry, FCCP, MRCPCH, Jazz Pharmaceuticals, Potassium, Pharmaceutical industry, Sleep, Gamma-Hydroxybutyric acid, MD, Medicine

DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023. One of the accepted abstracts provided a comprehensive review of clinical data that assessed the impact of oxybate on sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy. Oxybate is the active ingredient in Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution.

Key Points: 
  • Review of multiple clinical trials provided a comprehensive analysis showing that oxybate improves sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy, independent of once- or twice-nightly dosing
    DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023.
  • One of the accepted abstracts provided a comprehensive review of clinical data that assessed the impact of oxybate on sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy.
  • The review found that oxybate improved measures of sleep architecture and disrupted nighttime sleep in narcolepsy patients, independent of dosing regimen or prior oxybate experience.
  • "Idiopathic hypersomnia has a profound impact on those who live with this debilitating sleep disorder," said Kelvin Tan, MBBCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals.

ORYZON to Give Updates on Corporate Progress in September

Retrieved on: 
Tuesday, September 5, 2023
KOL, LSD1, BPD, CET, Vall, Genomics, Health, Genetic distance, CMT, Doctor of Philosophy, Teaching hospital, HDAC6, BME, ORY, Partner, MD, Borderline personality disorder, Medicine, ISIN, University of Manchester, MRCPCH, Lotte New York Palace Hotel, Growth, Neurodegenerative disease, Research, NHS, Mental health, Conference, Pharmaceutical industry, MBBS

Oryzon will participate at the H.C. Wainwright Global Investment Conference, which will be held on September 11-13 at the Lotte New York Palace Hotel in New York (USA) and virtually.

Key Points: 
  • Oryzon will participate at the H.C. Wainwright Global Investment Conference, which will be held on September 11-13 at the Lotte New York Palace Hotel in New York (USA) and virtually.
  • The company will provide a corporate update and will also hold one-on-one meetings with pharmaceutical companies and global investors.
  • Additionally, the company will present during the poster session the data obtained in a CMT experimental model with its selective HDAC6 inhibitor ORY-4001.
  • Executive directors of the company will attend BIO-Spain 2023, which will take place on September 26-28 in Barcelona, Spain.

Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023
Epilepsy, Cognition, Abstract, LGS, Idiopathic disease, IHSS, Prevalence, MB, Sodium oxybate, Magnesium, AAN, DSM-IV codes, SEGUE, Clinical trial, Trial of the century, Narcolepsy, American Academy, ARISE, DS, Calcium, Hypertension, ESS, ET, Dravet syndrome, Patient, Risk, Epworth Sleepiness Scale, Lennox–Gastaut syndrome, MRCPCH, Neurology, Jazz Pharmaceuticals, Cannabidiol, Sleep, Potassium, Function (mathematics), Idiopathic hypersomnia, Treatment, Total, Caregiver, Safety, Pharmaceutical industry, Nightclub, Xywav

DUBLIN, April 19, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including three oral presentations, will be featured at the 75th Annual American Academy of Neurology Meeting (AAN) being held April 22-27, 2023 in Boston.

Key Points: 
  • Eleven abstracts emphasize Jazz's leadership in neuroscience and commitment to advance understanding of sleep disorders, epilepsy and movement disorders
    DUBLIN, April 19, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including three oral presentations, will be featured at the 75th Annual American Academy of Neurology Meeting (AAN) being held April 22-27, 2023 in Boston.
  • "Jazz has long been at the forefront of providing novel therapies and support for patients living with serious neurologic conditions.
  • Highlights at the 2023 AAN Annual Meeting include:
    Three posters demonstrating the impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates), the first and only low-sodium oxybate, on narcolepsy patients.
  • Two oral presentations of retrospective analyses of U.S. healthcare claims that estimate the prevalence of diagnosed and drug-treated essential tremor (ET) in adult and pediatric patients.

Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023
Epilepsy, Cognition, Abstract, LGS, Idiopathic disease, IHSS, Prevalence, MB, Sodium oxybate, Magnesium, AAN, DSM-IV codes, SEGUE, Clinical trial, Trial of the century, Narcolepsy, American Academy, ARISE, DS, Calcium, Hypertension, ESS, ET, Dravet syndrome, Patient, Risk, Epworth Sleepiness Scale, Lennox–Gastaut syndrome, MRCPCH, Neurology, Jazz Pharmaceuticals, Cannabidiol, Sleep, Potassium, Function (mathematics), Idiopathic hypersomnia, Treatment, Total, Caregiver, Safety, Pharmaceutical industry, Nightclub, Xywav

DUBLIN, April 19, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including three oral presentations, will be featured at the 75th Annual American Academy of Neurology Meeting (AAN) being held April 22-27, 2023 in Boston.

Key Points: 
  • Eleven abstracts emphasize Jazz's leadership in neuroscience and commitment to advance understanding of sleep disorders, epilepsy and movement disorders
    DUBLIN, April 19, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including three oral presentations, will be featured at the 75th Annual American Academy of Neurology Meeting (AAN) being held April 22-27, 2023 in Boston.
  • "Jazz has long been at the forefront of providing novel therapies and support for patients living with serious neurologic conditions.
  • Highlights at the 2023 AAN Annual Meeting include:
    Three posters demonstrating the impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates), the first and only low-sodium oxybate, on narcolepsy patients.
  • Two oral presentations of retrospective analyses of U.S. healthcare claims that estimate the prevalence of diagnosed and drug-treated essential tremor (ET) in adult and pediatric patients.

STAND UP TO CANCER LAUNCHES NEW RADIO PSA WITH JAZZ PHARMACEUTICALS TO ENCOURAGE LUNG CANCER SCREENING

Retrieved on: 
Monday, November 14, 2022
Jazz Pharmaceuticals, MRCPCH, Doctor of Philosophy, PSA, KRAS, Tobacco Products Scientific Advisory Committee, Radon, FAC, SU2C, Entertainment Industry Foundation, Awareness, Partnership, Safety, Non-Smokers' Rights Association, Cancer, Research, Noreen Fraser Foundation, Smoking, Squamous cell carcinoma, Multimedia, Lung cancer, Patient, Small-cell carcinoma, Air pollution, CEO, Stand Up to Cancer, Large-cell lung carcinoma, Diagnosis, Radio, Young adult, Disease, Smoke, Pharmaceutical industry, Black, Adolescence

The PSA aims to raise awareness in Black and Hispanic communities about small cell lung cancer and encourage listeners to learn about screening options.

Key Points: 
  • The PSA aims to raise awareness in Black and Hispanic communities about small cell lung cancer and encourage listeners to learn about screening options.
  • "Additionally, we are incredibly thankful to Jazz Pharmaceuticals for the company's support of SU2C's Catalystprogram, including research to investigate potential new treatments for non-small cell lung cancer."
  • "Jazz is committed to transforming the lives of patients and their families, and our collaboration with Stand Up To Cancer on this PSA campaign aims to spread awareness of small cell lung cancer and encourage early screening.
  • Stand Up To Cancer recently announced the funding of three SU2C Catalyst research projects with support from Jazz Pharmaceuticals.

Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-120 for the Treatment of Giant Axon Neuropathy (GAN)

Retrieved on: 
Tuesday, May 3, 2022
COVID-19, Drug development, Forward-looking statement, Population, Private Securities Litigation Reform Act, European Commission, Nasdaq, Union, Giant axonal neuropathy, MRCP, GLOBE, MRCPCH, CNS, Development, Death, National Institute, AAV, NIH, Safety, Food, Â, Patient, Genetic disorder, Royal commission, FFPM, Clinical trial, FDA, Diagnosis, Annual report, Neurodegeneration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, National, Leadership, Lists of diseases, NINDS, National Institute of Neurological Disorders and Stroke, Quality of life, Disease, GeneDx, SEC, GAN, Biopsy, Awareness, Central nervous system, Risk, Pharmaceutical industry, Research, MBBS, Stroke

We are pleased to receive orphan drug designation by the European commission which can help facilitate rapid clinical advancement and subsequent access to patients as we further approach regulatory approval.

Key Points: 
  • We are pleased to receive orphan drug designation by the European commission which can help facilitate rapid clinical advancement and subsequent access to patients as we further approach regulatory approval.
  • TSHA-120 has previously received Orphan Drug and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA).
  • The European Commission grants orphan drug designation for medicines being developed for the diagnosis, prevention or treatment of treat life-threatening or chronically debilitating conditions that affect fewer than 5 in 10,000 people in the European Union.
  • Orphan designation in the European Union includes benefits such as protocol assistance, reduced regulatory fees and market exclusivity.

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome

Retrieved on: 
Tuesday, March 29, 2022
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Rett syndrome, Spinal cord, Private Securities Litigation Reform Act, Intellectual disability, Profile, Drug development, University of Texas Southwestern Medical Center, FFPM, CTA, Human, DRS, DNA, Seizure, Forward-looking statement, Patient, AAV, European Commission, GLP, Central nervous system, Survival, CNS, SEC, Toxicology, Mirare, MRCPCH, Food, Tissue, Prevalence, Quality of life, Royal commission, RNA transfection, Neurodevelopmental disorder, Nasdaq, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, Mutation, MRCP, DRG, U.S. Securities and Exchange Commission, IRSF, Development, Annual report, FDA, Health Canada, Disease, Toxicity, Gene, Pharmaceutical industry, MECP2, Rett, Research, MBBS, TSHA-102 AND MIRARE, RETT SYNDROME, TAYSHA GENE THERAPIES

Initiation of clinical development is a significant milestone for the TSHA-102 program and Rett syndrome community, said Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Chief Medical Officer and Head of Research and Development of Taysha.

Key Points: 
  • Initiation of clinical development is a significant milestone for the TSHA-102 program and Rett syndrome community, said Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Chief Medical Officer and Head of Research and Development of Taysha.
  • Dr. Prasad added, There are no disease-modifying therapies to treat over 350,000 patients estimated to suffer from Rett syndrome worldwide2.
  • These preclinical safety and efficacy data will be presented at the International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting taking place April 26-27, 2022 in Nashville, Tennessee.
  • TSHA-102 is a self-complementary intrathecally delivered AAV9 gene replacement therapy under development for the treatment of Rett syndrome.

Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium

Retrieved on: 
Wednesday, February 9, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Fluid mechanics, Private Securities Litigation Reform Act, MFSD8, Forward-looking statement, Neurodegeneration, CSF, Clinical Global Impression, Bone marrow suppression, Severe cognitive impairment, Gene, Batten disease, Toxicity, Seizure, CNS, Annual report, U.S. Securities and Exchange Commission, Clinical trial, Inflammation, Incidence, Quality of life, FDA, Patient, Safety, MRCP, Brain, SEC, Central nervous system, Human, UTSW, Death, AAV, Speech, Drug development, Nasdaq, Disease, MRCPCH, FFPM, Ataxia, Development, COVID-19, Pharmaceutical industry, MBBS, University of Texas Southwestern Medical Center, Research

The primary endpoint of the trial is safety and tolerability by incidence and severity of treatment related serious adverse events.

Key Points: 
  • The primary endpoint of the trial is safety and tolerability by incidence and severity of treatment related serious adverse events.
  • Taysha holds the exclusive option to license the CLN7 Batten disease program from UT Southwestern.
  • CLN7 Batten disease is a rare, fatal, and rapidly progressive neurodegenerative disease that is a form of Batten disease.
  • Currently, there are no approved therapies to treat CLN7 Batten disease, which impacts an estimated 4,000 patients globally.